Rubella virus is an enveloped RNA virus from the Togaviridae family. Rubella virus is included in the so-called TORCH infections, which are especially dangerous for pregnant women. IgM specific immunoglobulins appear first in the blood after vaccination and at the primary infection with the rubella virus. After the infection IgM antibodies are registered on the 3-5th day from the appearance of the rash, and after vaccination, antibodies of this class begin to appear in the blood in the third or fourth week. Specific antibodies of the IgG class begin to be produced by the body 7-10 days after clinical manifestations and reach a maximum after 4-5 weeks and remain at a high level for a long time. For this reason, it is quite difficult to determine acute infection using serodiagnosis. However, it is common knowledge that the avidity of an antibody increases over time. As the immune response matures, low avidity antibodies are replaced by high avidity antibodies. Detection of anti-rubella IgG with low avidity indicates recent infection. A high aqueous content of IgG to the rubella virus indicates more distant contact with rubella, which may be a consequence of a history of infection or long-term vaccination.
Vitrotest has developed both high avidity and low avidity monoclonal antibodies to Rubella virus. Antibodies are obtained against native antigens and are carefully tested for suitability in ELISA tests. Some clones are suitable for creating affinity carriers for the purification of native Rubella virus antigens. All monoclonal antibodies can be used to prepare synthetic positive controls and calibrators for quantitative immunoassays. The internal controls we offer will allow you to abandon the search for extremely scarce raw materials to create control material for tests for class M antibodies, as well as for the avidity of class G antibodies. Our specialists will be happy to advise and recommend the best list of monoclonal antibodies for your production.
